Significance of serine threonine tyrosine kinase 1 as a drug resistance factor and therapeutic predictor in acute leukemia

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 1867-1874

  Nirasawa, Shinya ^a   Kobayashi, Daisuke ^a   Kondoh, Takashi ^a   Kuribayashi, Kageaki ^a   Tanaka, Maki ^a   Yanagihara, Nozomi ^a   Watanabe, Naoki ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Acute leukemia; Chemo resistance; MRNA expression; Prediction; Serine threonine tyrosine kinase 1

Indexed keywords

CASPASE 3; CASPASE 7; DOXORUBICIN; EPHRIN RECEPTOR A4; ETOPOSIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 4; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SERINE THREONINE KINASE 31; SERINE THREONINE TYROSINE KINASE 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 3; PROTEIN KINASE B; SALL4 PROTEIN, HUMAN; STYK1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ACUTE LEUKEMIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; R FACTOR; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HL 60 CELL LINE; LEUKEMIA; METABOLISM; PATHOLOGY;

CASPASE 3; CELL PROLIFERATION; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, LEUKEMIC; HL-60 CELLS; HUMANS; LEUKEMIA; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 84907189436     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2633     Document Type: Article

References (18)

1. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al: Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10: 1911-1918, 1996.
2. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R and Scapozza L: Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 4: 75-85, 2003.
3. Paietta E, Ferrando AA, Neuberg D, et al: Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood 104: 558-560, 2004.
4. Yanada M, Takeuchi J, Sugiura I, et al: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24: 460-466, 2006.
5. Wang YY, Zhou GB, Yin T, et al: AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: Implication in stepwise leukemogenesis and response to Gleevec. Proc Natl Acad Sci USA 102: 1104-1109, 2005.
6. George P, Bali P, Cohen P, et al: Cotreatment with 17-Allylaminodemethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3. Cancer Res 64: 3645-3652, 2004.
7. Kondoh T, Kobayashi D, Tsuji N, Kuribayashi K and Watanabe N: Overexpression of serine threonine tyrosine kinase 1/novel oncogene with kinase domain mRNA in patients with acute leukemia. Exp Hematol 37: 824-830, 2009.
8. Liu L, Yu XZ, Li TS, et al: A novel protein tyrosine kinase NOK that shares homology with platelet-derived growth factor/fibroblast growth factor receptors induces tumorigenesis and metastasis in nude mice. Cancer Res 64: 3491-3499, 2004.
9. Chen Y, Li YH, Chen XP, et al: Point mutation at single tyrosine residue of novel oncogene NOK abrogates tumorigenesis in nude mice. Cancer Res 65: 10838-10846, 2005.
10. Ma Y, Cui W, Yang J, et al: SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood 108: 2726-2735, 2006.
11. Gupta R, Hong D, Iborra F, Sarno S and Enver T: NOV (CCN3) functions as a regulator of human hematopoietic stem or progenitor cells. Science 316: 590-593, 2007.
12. Jeong HW, Cui W, Yang Y, Lu J, He J, Li A, Song D, Guo Y, Liu BH and Chai L: SALL4, a stem cell factor, affects the side population by regulation of the ATP-binding cassette drug transport genes. PLoS One 6: E18372, 2011.
13. Bard JD, Gelebart P, Amin HM, Young LC, Ma Y and Lai R: Signal transducer and activator of transcription 3 is a transcriptional factor regulating the gene expression of SALL4. FASEB J 23: 1405-1414, 2009.
14. Tazzari PL, Cappellini A, Ricci F, et al: Multidrug resistanceassociated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21: 427-438, 2007.
15. Chiarini F, Del Sole M, Mongiorgi S, et al: The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-Acute leukemia cells by a JNK-dependent mechanism. Leukemia 22: 1106-1116, 2008.
16. Moriai R, Kobayashi D, Amachika T, Tsuji N and Watanabe N: Diagnostic relevance of overexpressed NOK mRNA in breast cancer. Anticancer Res 26: 4969-4973, 2006.
17. Amachika T, Kobayashi D, Moriai R, Tsuji N and Watanabe N: Diagnostic relevance of overexpressed mRNA of novel oncogene with kinase-domain (NOK) in lung cancers. Lung Cancer 56: 337-340, 2007.
18. Harbott J, Viehmann S, Borkhardt A, Henze G and Lampert F: Incidence of TEL/AML1 fusion gene analyzed consecutively in children with acute lymphoblastic leukemia in relapse. Blood 90: 4933-4937, 1997.